Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Trea H Winter"'
Autor:
Hanneke J van der Woude, Marinus van Hulst, R. Aalbers, Johan Zaagsma, Trea H Winter, Dirkje S. Postma
Publikováno v:
Chest. 127:818-824
Introduction β-Blockers are known to worsen FEV 1 and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring β-blocker treatment Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5327be94be9450f41de3d4dc49970b46
https://doi.org/10.1378/chest.127.3.818
https://doi.org/10.1378/chest.127.3.818
Publikováno v:
Respiratory Medicine, 98(9), 816-820. W B SAUNDERS CO LTD
Virtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid onset of bronchodilating effect, whereas salmeterol acts slower. We studied the onset of improvement of dyspnoea sensation after inhalation with these bronchodi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4a153024a5bb016a31858d23459c15
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 17:89-95
Inhalers containing corticosteroids and long-acting beta2-agonists are becoming increasingly important in asthma management. A rapid effect is important to patients, particularly during exacerbations. We compared the onset of bronchodilation and pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70fddd818b928f2d41e6e242c7366c30
https://doi.org/10.1016/j.pupt.2003.11.001
https://doi.org/10.1016/j.pupt.2003.11.001
Autor:
Hanneke J, van der Woude, Johan, Zaagsma, Dirkje S, Postma, Trea H, Winter, Marinus, van Hulst, René, Aalbers
Publikováno v:
Chest. 127(3)
beta-Blockers are known to worsen FEV(1) and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring beta-blocker treatment.To determine the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51d7fdd09e281590c03a777e86647e53
https://pubmed.ncbi.nlm.nih.gov/15764762
https://pubmed.ncbi.nlm.nih.gov/15764762
BACKGROUND—In vitro the long acting β2 agonist salmeterol can, in contrast to formoterol, behave as a partial agonist and become a partial antagonist to other β2 agonists. To study this in vivo, the bronchodilating effect of salbutamol was measur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e52d43b12fdb9a68ed1a9afd506dad8
https://europepmc.org/articles/PMC1746085/
https://europepmc.org/articles/PMC1746085/
